Skip to main content
[Preprint]. 2023 Feb 3:2023.02.02.526674. [Version 1] doi: 10.1101/2023.02.02.526674

Fig. 4. Responses of NF1-MPNST cells to the CDK4/6i ribociclib.

Fig. 4.

(A) Ten NF1-associated MPNST cell lines were treated with increasing dose of the CDK4/6i ribociclib for five days. Cell viability was evaluated by using the CCK-8 assay. (B) Two NF1-MPNST cell lines were treated with DMSO or 1 μmol/L ribociclib over a time course. Signal intermediates in ERK and cell cycle pathways were assessed. (C) JH-2–002 cells were treated with DMSO or 1 μmol/L ribociclib for 24 hours. 71 phosphorylated human receptor tyrosine kinases (RTK) were evaluated using human RTK phosphorylation array C1. Signal intensity from technical duplicates was quantified using densitometry analysis, normalized to ribociclib v. DMSO, and significantly altered RTKs are shown. (D) Cells as in Fig 3E were treated with increasing doses of ribociclib for five days. Cell viability was evaluated by using the CCK-8 assay.